Title
Dermatophytosis: Clinical profile and resistance to itraconazole and terbinafine
Authors
Shivank Shrivastav1, Suneel Singh Sengar2, Varun Kumar1,*& Amardeep Malviya1
Affiliation
1Department of Dermatology, AIMS, Dewas, Madhya Pradesh, India; 2Department of Dermatology, SSMC, Rewa, Madhya Pradesh, India; *Corresponding author
Shivank Shrivastav- E-mail: shivank24@gmail.com
Suneel Singh Senger- E-mail: suneelsinghsengar@gmail.com
Varun Kumar- E-mail: varunkumarshobha@gmail.com
Amardeep Malviya- E-mail: amardeepmlv97@gmail.com
Article Type
Research Article
Date
Received July 1, 2026; Revised July 31, 2026; Accepted July 31, 2026, Published July 31, 2026
Abstract
Globally, 20-25% of the population suffers from dermatophytosis. In India, there is an increase in treatment resistance and an epidemiological shift towards Trichophyton mentagrophytes. This was a prospective study, which randomized 500 patients of dermatophyte infection to either oral itraconazole or terbinafine to find out the rising treatment failure. Tinea cruris was the prevalent diagnosis (37.2%, M:F ratio 2.16:1), with Trichophyton mentagrophytes the commonest pathogen isolated. The clinical resistance of terbinafine was significantly higher than itraconazole (24.4% versus 5.2%, p < 0.0001). With no real mycological resistance found, clinical failure was mainly due to non-compliance (44.6%), diabetes and co-existing onychomycosis. Thus, data show the best first-line therapy is likely itraconazole and dealing with host co-morbidities probably overcomes treatment failure.
Keywords
Dermatophytosis, itraconazole, terbinafine
Citation
Shrivastav et al. Bioinformation 22(7): 4528-4532 (2026)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
